The biodistribution of 5-[18F] fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Zhang, Zhuo ^a   Ordonez, Alvaro A ^b   Smith Jones, Peter ^a   Wang, Hui ^a   Gogarty, Kayla R ^a   Daryaee, Fereidoon ^a   Bambarger, Lauren E ^b   Chang, Yong S ^b   Jain, Sanjay K ^b   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUOROPYRAZINAMIDE F 18; BACTERIAL ENZYME; HALIDE; HALOGEN; PYRAZINAMIDASE; PYRAZINAMIDE; RADIOISOTOPE; UNCLASSIFIED DRUG; AMIDASE; FLUORINE; PYRAZINAMIDE DEAMIDASE; RADIOPHARMACEUTICAL AGENT; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOCHEMICAL ANALYSIS; BRAIN; COMPUTED TOMOGRAPHY SCANNER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEFLUORINATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KIDNEY; LIVER; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUSCLE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RADIOISOTOPE DECAY; RADIOISOTOPE DISTRIBUTION; TUBERCULOSIS; ANALOGS AND DERIVATIVES; ANIMAL; C3H MOUSE; DIAGNOSTIC IMAGING; DRUG EFFECTS; ENZYME SPECIFICITY; LUNG TUBERCULOSIS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TISSUE DISTRIBUTION;

AMIDOHYDROLASES; ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; FLUORINE RADIOISOTOPES; MICE; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PYRAZINAMIDE; RADIOPHARMACEUTICALS; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION; TUBERCULOSIS, PULMONARY;

EID: 85011545888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170871     Document Type: Article

References (34)

1. Dawson R, Van Niekerk C, Erondu N, Ginsberg A, editors. P-931aPyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis. ICAAC; 2011 Sep 18, 2011; Chicago, IL.
2. American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. The American review of respiratory disease. 1986; 134(2):355-63. Epub 1986/08/01. PMID: 3527010.
3. Sun Z, Scorpio A, Zhang Y. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Microbiology (Reading, England). 1997; 143 (Pt10):3367-73. Epub 1997/11/14.
4. Boshoff HI, Mizrahi V, Barry CE 3rd. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. Journal of bacteriology. 2002; 184(8):2167-72. Epub 2002/03/27. doi:10.1128/JB.184.8.2167-2172.2002 PMID: 11914348.
5. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: A review. The international journal of tuberculosis and lung disease: The official journal of the International Union against Tuberculosis and Lung Disease. 2003; 7(1):6-21.
6. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: A systematic review with meta-Analyses. Antimicrobial agents and chemotherapy. 2011; 55(10):4499-505. Epub 2011/07/20. doi:10.1128/AAC.00630-11 PMID: 21768515.
7. Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, et al. Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS infectious diseases. 2015; 1(5):203-14. Epub 2015/06/19. doi:10.1021/id500028m PMID: 26086040.
8. Singh P, Mishra AK, Malonia SK, Chauhan DS, Sharma VD, Venkatesan K, et al. The paradox of pyrazinamide: An update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. The Journal of communicable diseases. 2006; 38(3):288-98. Epub 2007/03/22. PMID: 17373362.
9. Pyrazinamide. Tuberculosis (Edinburgh, Scotland). 2008; 88(2):141-4. Epub 2008/05/20.
10. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nature medicine. 2000; 6(9):1043-7. Epub 2000/09/06. doi:10.1038/79558 PMID: 10973326.
11. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE 3rd, et al. Pyrazinamide inhibits trans-Translation in Mycobacterium tuberculosis. Science (New York, NY). 2011; 333(6049):1630-2. Epub 2011/08/13.
12. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature medicine. 1996; 2(6):662-7. Epub 1996/06/01. PMID: 8640557.
13. Baughn AD, Deng J, Vilcheze C, Riestra A, Welch JT, Jacobs WR Jr., et al. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy. Antimicrobial agents and chemotherapy. 2010; 54(12):5323-8. Epub 2010/09/30. doi:10.1128/AAC.00529-10 PMID: 20876380.
14. Cynamon MH, Speirs RJ, Welch JT. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrobial agents and chemotherapy. 1998; 42(2):462-3. Epub 1998/04/04. PMID: 9527809.
15. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003; 131(1):48-52. Epub 2003/01/10. doi:10.1046/j.1365-2249.2003.02031.x PMID: 12519385.
16. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature medicine. 2015; 21(10):1223-7. Epub 2015/09/08. doi:10.1038/nm.3937 PMID: 26343800.
17. Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, et al. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS infectious diseases. 2016; 2(4):251-67. doi:10.1021/acsinfecdis.5b00127 PMID: 27227164.
18. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis. 2012; 205(4):595-602. doi:10.1093/infdis/jir786 PMID: 22198962.
19. Ordonez AA, Tasneen R, Pokkali S, Xu Z, Converse PJ, Klunk MH, et al. Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Disease Models and Mechanisms. 2016; 9(7):779-88. doi:10.1242/dmm.025643 PMID: 27482816.
20. Wayne LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. The American review of respiratory disease. 1974; 109(1):147-51. Epub 1974/01/01. PMID: 4203284.
21. Singh P, Wesley C, Jadaun GP, Malonia SK, Das R, Upadhyay P, et al. Comparative evaluation of Lowenstein- Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Journal of clinical microbiology. 2007; 45(1):76-80. Epub 2006/11/10. doi:10.1128/JCM.00951-06 PMID: 17093022.
22. Heifets L, Sanchez T. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. Journal of clinical microbiology. 2000; 38(4):1498-501. PMID: 10747133.
23. Ordonez AA, Weinstein EA, Bambarger LE, Saini V, Chang YS, DeMarco VP, et al. A Systematic Approach for Developing Bacteria-Specific Imaging Tracers. J Nucl Med. 2016.
24. Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM, Pokkali S, MacDonald EM, et al. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med. 2014; 6(259):259-146. doi:10.1126/scitranslmed.3009815 PMID: 25338757.
25. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, et al. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrobial agents and chemotherapy. 2009; 53(11):4879-84. doi:10.1128/AAC.00789-09 PMID: 19738022.
26. Weinstein EA, Liu L, Ordonez AA, Wang H, Hooker JM, Tonge PJ, et al. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrobial agents and chemotherapy. 2012; 56(12):6284-90. doi:10.1128/AAC.01644-12 PMID: 23006755.
27. DeMarco VP, Ordonez AA, Klunk M, Prideaux B, Wang H, Zhuo Z, et al. Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging. Antimicrobial agents and chemotherapy. 2015; 59(9):5768-74. doi:10.1128/AAC.01146-15 PMID: 26169396.
28. Furuya T, Kuttruff CA, Ritter T. Carbon-fluorine bond formation. Current opinion in drug discovery & development. 2008; 11(6):803-19. Epub 2008/10/24.
29. Preshlock S, Tredwell M, Gouverneur V. (18)F-Labeling of Arenes and Heteroarenes for Applications in Positron Emission Tomography. Chemical reviews. 2016; 116(2):719-66. Epub 2016/01/12. doi:10.1021/acs.chemrev.5b00493 PMID: 26751274.
30. Cynamon MH, Gimi R, Gyenes F, Sharpe CA, Bergmann KE, Han HJ, et al. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. Journal of medicinal chemistry. 1995; 38(20):3902-7. PMID: 7562923.
31. Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, et al. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. The Indian journal of medical research. 2012; 136(5):808-14. PMID: 23287128.
32. Manca C, Koo MS, Peixoto B, Fallows D, Kaplan G, Subbian S. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PloS one. 2013; 8(8):e74082. doi:10.1371/journal.pone.0074082PMID: 24015316.
33. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerging microbes & infections. 2013; 2(6):e34.
34. Ordonez AA, DeMarco VP, Klunk MH, Pokkali S, Jain SK. Imaging Chronic Tuberculous Lesions Using Sodium [(18)F]Fluoride Positron Emission Tomography in Mice. Molecular imaging and biology: MIB: The official publication of the Academy of Molecular Imaging. 2015; 17(5):609-14. Epub 2015/03/10.